Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB

Background: Rifampicin is the key drug responsible for sterilizing activities in the first-line TB treatment regimen. Damage to the gut during acute and chronic HIV infection may inhibit drug absorptive capacity. We sought to test the hypothesis that markers of intestinal damage, bacterial transloca...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Antimicrob Chemother
Autori principali: Vinnard, Christopher, Ravimohan, Shruthi, Tamuhla, Neo, Pasipanodya, Jotam, Srivastava, Shashikant, Modongo, Chawangwa, Zetola, Nicola M., Weissman, Drew, Gumbo, Tawanda, Bisson, Gregory P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890696/
https://ncbi.nlm.nih.gov/pubmed/28472448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkx111
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi